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Abstract
Background and Aim L-Acetyl-carnitine (LAC) exerts an
energetic effect on nerves and muscles. Recently, preclin-
ical experiments have demonstrated a central anti-noci-
ceptive action.
Objective Our objective was to assess the effects of LAC
on neuroprotection, pain, and function in carpal tunnel
syndrome (CTS), a very frequent chronic compressive
neuropathy.
Methods In a multicentre, examiner-blinded, clinical and
neurophysiological 4-month study, we enrolled 82 patients
and examined 120 hands with CTS of mild to moderate
severity. Patients were assessed at baseline and 10, 60 and
120 days after treatment with LAC 500 mg twice daily
(BID). All patients underwent a conduction study of the
median nerve, the Boston Carpal Tunnel Questionnaire
(BCTQ) and the Neuropathic Pain Symptom Inventory
(NPSI). The primary endpoint was the sensory conduction
velocity (SCV) of the median nerve.
Results The primary endpoint was met, with significant
improvement of the SCV (P\0.0001). All sensory neu-
rophysiological measures also significantly improved.
BCTQ score changed significantly (P\0.0001), with a
greater improvement in the symptom component. Nine of
the NPSI types of pain, particularly squeezing and pressure
pain and pain evoked by pressure, showed a significant
reduction (P\0.0001).
Conclusions Our clinical and neurophysiological study
indicated that 4 months of treatment with LAC exerted a
neuroprotective effect. LAC reduced pain in patients with
mild and moderate CTS, a result that is possibly due to
both its neuroprotective action and its central anti-noci-
ceptive properties.
Clinical Trials Registration code: EudraCT 2014-002289-
62.
Key Points
L-Acetyl-carnitine exerts a neuroprotective effect in
patients with carpal tunnel syndrome of mild to
moderate severity.
L-Acetyl-carnitine reduces pain in patients with mild
and moderate carpal tunnel syndrome, possibly due
to both its neuroprotective action and its central anti-
nociceptive properties.
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1 Introduction
Compressive neuropathies have comparatively been
neglected by drug companies, in terms of both neuropro-
tection and pain, whereas very many clinical trials have
been performed in distal symmetric polyneuropathies, such
as diabetic or chemotherapy-induced neuropathy. Esti-
mates of the prevalence of diabetic neuropathy, the most
frequent length-dependent neuropathy, range widely
between 1.3 and 2% [1–3]. Those for carpal tunnel syn-
drome (CTS), the most frequent compressive neuropathy,
also range widely between 2 and 5% [4–6], with a higher
prevalence when diagnosed using a nerve conduction study
(NCS) versus clinical examination [4]. Such values refer to
the general population; specific working categories reach
greater prevalence [7].
In neurological departments, these two neuropathies are,
by far, the two most frequently diagnosed. Nevertheless,
when we searched PubMed, only 19 clinical trials inves-
tigated chronic oral treatments in CTS compared with
about 200 for diabetic neuropathy [8].
L-Acetyl-carnitine (LAC) has been found to exert a
neuroprotective effect in patients with various types of
peripheral neuropathy, including CTS [9]. Recently, stud-
ies in small mammals have demonstrated LAC’s central
action in experimental pain models, both neuropathic and
inflammatory [10].
These two issues, together with the scarcity of trials in
CTS, led us to test the efficacy of LAC on nerve conduc-
tion, pain and hand function in patients with mild to
moderate CTS. The primary outcome was an improvement
of the sensory conduction velocity (SCV) of the median
nerve.
2 Methods
2.1 Participants
Sample size calculation led to an estimation of 70 patients
plus 10–15% to compensate for probable discontinuations.
Patients aged between 18 and 65 years, with a diagnosis of
mild to moderate CTS as defined by the criteria of Padua
et al. [11] and duration of symptoms no longer than
12 months were included in the study. Key exclusion cri-
teria included other peripheral nerve diseases, medical
conditions potentially associated with polyneuropathy and
orthopaedic conditions affecting the wrist. Electronic
Supplementary Material (ESM) 1 provides the list of all
inclusion and exclusion criteria and the rules for con-
comitant drugs. Written informed consent was obtained
from all participants before study-related procedures. The
study protocol, patient information and informed consent
forms were reviewed and approved by the Institutional
Review Board at the participant hospitals.
2.2 Study Design
In this multicentre, examiner-blinded, clinical and neuro-
physiological study, eligible subjects were assessed at
baseline and 10, 60 and 120 days after treatment (Fig. 1).
The study lasted 4 months, corresponding to the dura-
tion of the treatment. The screening period did not have a
fixed duration, but in most cases the enrolment occurred
during the screening visit. The recruitment period lasted
18 months, from May 2015 to November 2016.
The clinical trial included five neurology hospital clinics
with expert staff for electrophysiology and pain.
The treatment phases consisted of an initial 10-day
period of intramuscular injections of LAC 500 mg twice
daily (BID) followed by a 110-day period of oral treatment
with one tablet of LAC 500 mg BID. Patients who did not
reach 80% of the target dosage at any visit were discon-
tinued for poor compliance.
In total, 85 patients (125 hands) with mild to moderate
CTS were screened. Three did not complete the procedures
foreseen in the enrolment visit, resulting in screening
failures. Therefore, 82 patients (25 men, 57 women; mean
age 47.1± 9.0 years) were enrolled (corresponding to 120
hands, 63 mild CTS and 57 moderate CTS). Nine discon-
tinued the treatment: eight withdrew consent and one was
discontinued for poor compliance.
All patients underwent neurophysiological recording of
sensory and motor nerve conduction as well as the Douleur
Neuropathique 4 (DN4) to identify neuropathic pain [12],
Neuropathic Pain Symptom Inventory (NPSI) to rate var-
ious types of pain [13] and Boston Carpal Tunnel Ques-
tionnaire (BCTQ) to assess hand function [14] at baseline
and after 10, 60 and 120 days. The three questionnaires can
be found in ESM 2.
Safety evaluations, including assessments of adverse
events, vital signs, laboratory measures, and physical
examination findings were performed during each sched-
uled visit.
Possible adverse events, either volunteered sponta-
neously by patients or in response to general non-leading
questioning by the investigator, were recorded from the
start of treatment on day 0 until the final day-120 visit.
2.3 Assessments
2.3.1 Neurophysiological Assessment
At screening, patients underwent an NCS to both classify
the severity of CTS and to control for other peripheral
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neuropathies. Neurophysiological recordings and mea-
surements were performed by specific medical staff. In
particular, measures were taken by examiners who were
blinded to the patient’s condition. To assess CTS, patients
underwent a motor and sensory NCS using surface-
recording electrodes with standard placement. NCS inclu-
ded amplitude and conduction velocity of sensory nerve
action potentials (SAPs) recorded from the median nerve at
the wrist, after first and third finger stimulation. We also
measured the median-nerve compound motor action
potential (CMAP) amplitude and latency after stimulation
of the wrist and recording from thenar eminence. These
methods adhered to those recommended by experts of the
International Federation of Clinical Neurophysiology [15].
2.3.2 Hand Dysfunction Assessment
Hand dysfunction severity was evaluated during each
scheduled visit using the BCTQ, the most commonly used
questionnaire for the measurement of symptom severity
and functional status with reproducibility, internal consis-
tency, and validity in patients with CTS [14]. It includes
two parts: symptom and functional evaluation. The first
part comprises 11 items that can be scored from 1 (no
symptom) to 5 (severe), with the total score ranging from
11 (best) to 55 (worst). The second part comprises eight
items evaluating difficulty while performing daily tasks.
The responses are also scored using a 5-point scale, for a
total score ranging from 8 (best) to 40 (worst).
2.3.3 Pain Assessment
We used the DN4 questionnaire to identify neuropathic
pain. DN4 is a clinician-administered questionnaire con-
sisting of ten items: seven, concerning the quality of pain,
are obtained by interviewing the patient, and three items
are based on clinical examination and analyse the presence
or absence of touch or pinprick hypoesthesia and tactile
allodynia. A score of 1 is given to each positive item and a
score of 0 to each negative item. ScoresC 4/10 are con-
sidered indicative of neuropathic pain [12].
Pain intensity was rated at each scheduled visit by
means of the NPSI questionnaire, a self-administered
questionnaire specifically designed to evaluate the various
types of pain [13]. This questionnaire includes a list of ten
descriptors (plus two temporal items, questions 4 and 7)
reflecting spontaneous ongoing or paroxysmal pain, evoked
pain (i.e. mechanical and thermal allodynia/hyperalgesia)
and dysesthesia/paresthesia. Each of these items is
Fig. 1 Flow-chart of
participants and study design.
BID twice daily, ITT intention
to treat, NCS nerve conduction
study, t0, t10, t60, and t120
indicate the day of visit
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quantified on a numerical scale ranging from 0 to 10,
allowing discrimination and quantification of distinct pain
qualities.
2.4 Outcomes
The SCV of the median nerve was the primary endpoint.
SAP amplitude and CMAP latency and amplitude were
assessed as secondary endpoints. The secondary outcomes
also included the BCTQ to monitor symptom severity and
the NPSI as a measure of intensity of the various types of
pain. Outcome variables were monitored at baseline, 10, 60
and 120 days (Fig. 1). We also verified whether the
severity of CTS (mild vs. moderate) had an impact on the
outcome measures.
2.5 Statistics
All neurophysiological measures, being linear and nor-
mally distributed, were evaluated with analysis of variance
(ANOVA) for repeated measures with post hoc analysis for
linear trend. All the questionnaire scores, being non-linear
and occasionally non-normally distributed, were evaluated
with the Friedman test, Dunn’s multiple comparison test
and Wilcoxon’s matched pairs test. The differences
between mild and moderate CTS were evaluated with the
Mann–Whitney U test.
The missing values of the nine patients who discontin-
ued were treated as last observation carried forward
(LOCF), usual preference for linear measures provided by
laboratory tools such as those for neurophysiological
measures.
All statistics and graphs were created using Prism
(GraphPad, Sorrento Valley, CA, USA).
3 Results
3.1 Primary Outcome
In the 82 enrolled patients, the SCV of the median nerve, as
measured after stimulation of the third finger, was
36.6± 5.2 m/s at baseline (t0) and increased to
38.9± 6.8 m/s after 4 months of treatment (t120). As
evaluated with ANOVA for repeated measures, the dif-
ference was highly significant (P\0.0001). After stimu-
lation of the first finger, the SCV changed from
34.7± 5.6 m/s at t0 to 36.7± 6.6 m/s at t120 (P\0.0001).
The values were distributed linearly along time (Fig. 2),
with a positive linear trend to increase (P\0.0001) for
both fingers.
3.2 Other Neurophysiological Measures
From baseline to the end of the study, the amplitude of
sensory action potentials changed from 11.8± 8.6 to
14.1± 9.3 lV (P\0.0001) after stimulation of the third
finger and from 11.2± 6.2 to 13.7± 8.7 lV (P\0.0001)
after stimulation of the first finger, with a positive linear
trend to increase for both fingers.
The CMAPs did not improve as much as the sensory.
The latency shortened from 4.1± 0.9 to 3.9± 0.8 ms
(P\0.02). The amplitude change, from 8.2± 3.5 to
8.7± 3.3 mV, was not statistically significant.
3.3 Hand Dysfunction
Both the symptom and functional BCTQ scores signifi-
cantly decreased. The symptom BCTQ score decreased by
39%, from 19.3 (95% CI 17.6–21.1) at t0 to 11.8 (95% CI
10.3–13.2) at t120 (P\0.0001). The functional BCTQ
score decreased by 18%, from 15.2 (95% CI 13.9–16.5) at
t0 to 12.5 (95% CI 11.5–13.5) at t120 (18%; P\0.0001).
The Dunn’s multiple comparison test showed that the
time course of symptom and functional BCTQ scores did
not decrease between t60 and t120 (Fig. 3).
3.4 Pain
Of the 82 enrolled patients, only 44 (54%), corresponding
to 53 hands, had neuropathic pain, as assessed with DN4.
In all patients, we used the NPSI to assess the various
types of pain. We included in the NPSI analysis only the
hands scoring at least 4 in any 0–10 scale of the ten types
of pain considered in the NPSI. Therefore, our population
assessed with the NPSI included 77 hands in 58 patients. At
baseline, the type of pain scoring highest was tingling (6.8),
followed by pain evoked by pressure (4.1) and pins and
needles (3.7). Notably, burning pain, which is probably the
most frequent type of neuropathic pain, scored only 2.9.
Stabbing pain scored least (1.7) (Table 1).
In the course of the 4-month treatment period, all types
of pain decreased significantly, with the exception of
stabbing pain (Table 1). The effect size ranged from 38 to
56%, with the greatest pain relief reported for spontaneous
squeezing and pressure pains and pain evoked by pressure
(Table 1).
Estimated by the Wilcoxon test, the paired difference
between t0 and t120 were always significant, except for
stabbing pain (Table 1).
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3.5 Comparison Between Mild and Moderate
Carpal Tunnel Syndrome (CTS)
The severity of CTS did not affect the neurophysiological
or subjective outcome measures, except for a greater
shortening of CMAP latency in the hands with moderate
CTS (P = 0.026).
3.6 Adverse Events
No serious adverse events were reported during this study.
In total, 15 (18.3%) of the 82 patients enrolled reported a
total of 19 adverse events (18 were classified as mild and
one as moderate). None of these adverse events was con-
sidered related to treatment. Urinary tract infection was the
most common adverse event, occurring in eight (9.8%)
patients, followed by an increase of total bilirubin plasma
Fig. 2 Results of the median-
nerve conduction study in 82
patients. ANOVA analysis of
variance, CMAP compound
motor action potential, SAP
amplitude of the sensory action
potentials, SCV sensory
conduction velocity. Squares are
mean± standard error.
P ANOVA for repeated
measures. Note that all sensory
measures improve significantly
and linearly, whereas the
changes in amplitude of motor
potentials are not significant
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level in three (3.7%) and hypercholesterolemia in another
three (3.7%) patients. Remaining adverse events included
single cases of leukopenia, increased transaminases,
hyperglycaemia, colitis and haematuria. These adverse
events were evidenced by abnormal laboratory findings.
All patients were asymptomatic (including those with uri-
nary infections) (ESM 3).
4 Discussion
In this multicentre, examiner-blinded, clinical and neuro-
physiological study, we showed that 120 days of treatment
with LAC significantly improved the median-nerve SCV in
patients with mild or moderate CTS. LAC treatment also
had a positive impact on the patient-oriented measures
related to sensory function and pain.
4.1 Objective and Subjective Measures
Our clinical and neurophysiological study is an uncon-
trolled trial with no control group for comparison. We
admit that, in CTS, where sensory symptoms play a major
role, this is a serious limitation. However, bearing this
limitation in mind, we identified the SCV of the median
nerve as the primary endpoint and reported outcomes from
all patients as secondary outcome measures.
The SCV is an objective measure, uninfluenced by
possible placebo effects. Furthermore, the investigators
recording the NCS were not the same as those measuring
the NCS variables, and all were blinded to the patient’s
condition. Conversely, outcomes reported by patients may
include placebo effects. Accordingly, to address this
problem, we used the BCTQ to compare symptoms and
function and the NPSI questionnaire to compare the vari-
ous types of pain and verify whether the 4-month treatment
distinctly influenced the different variables. While we
admit that further, larger and controlled studies are needed
to confirm the efficacy of LAC on pain, we believe that our
data reliably support a neuroprotective effect of LAC.
The evidence of a neuroprotective effect of LAC relies
on the NCS changes. CTS-related variables (e.g. NCS) are
expected to remain unchanged over a short period and
worsen over a longer period [16–18]. In contrast, the NCS
variables in our patients significantly improved after
treatment.
4.2 Neuroprotective Effects
The linear improvement of sensory NCS variables with no
tendency to plateauing during the 4-month treatment period
support the neuroprotective effect of LAC. This effect is
probably mediated through various mechanisms that ulti-
mately restore mitochondrial activity [19, 20]. However,
our NCS data cannot show whether LAC treatment pro-
motes axonal regeneration or remyelination. Alternatively,
we cannot exclude that nerve fibers might have simply
benefitted from removal of conduction blocks.
In our study, we used median nerve SCV as the main
outcome measure. Admittedly, the relationship between
this neurophysiological variable and patients’ reported
symptoms (pain included) remains controversial [21];
however, the nerve conduction velocity provides an
objective measure, which is also widely used in animal
studies [22].
Among the different NCS variables, distal motor latency
showed a small but significant improvement during the
treatment period. Conversely the amplitude of the com-
pound muscle potentials did not significantly change
(Fig. 2). Our patients, who had mild or moderate CTS, may
have an increased latency of CMAPs; however, they were
required to have normal amplitude of CMAPs at the time of
inclusion (ESM 1).
Although distal motor latency change demonstrates that
LAC also exerts a positive effect on motor nerve fibers, the
effect size is smaller than that on sensory nerve fibers.
4.3 Pain in CTS
Pain did not seem to be the main problem for the majority
of our patients with mild to moderate CTS. Almost half of
Fig. 3 Boston Carpal Tunnel
Questionnaire (BCTQ). Squares
are mean± 95% confidence
intervals. P Friedman test. Note
that the effect size, although
statistically significant for both
BCTQ parts, is greater for the
symptom than for the functional
part
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the patients did not reach the DN4 threshold for neuro-
pathic pain, and an important proportion of hands and
patients did not reach a score of 4 in any of the ten types of
pain investigated with the NPSI. Patients with CTS may
experience both neuropathic and non-neuropathic (in-
flammatory or nociceptive) pain [6]. Given that previous
studies have also used NPSI for predominantly nociceptive
pain [23], we also applied this questionnaire to hands that
scored below the DN4 threshold. However, in the NPSI
analysis, we included only hands scoring at least 4 on any
of the NPSI measures of pain intensity, thus adhering to the
traditional cutoff adopted in clinical trials for pain.
At baseline, NPSI analysis showed that the most fre-
quent and severe type of sensory disturbance was tingling,
supposedly mediated by Ab fibers [24]. We hypothesize
that this finding might reflect the median nerve compres-
sion, which is expected to damage progressively from the
largest- to the smallest-diameter nerve fibers [25].
LAC treatment predominantly relieved pressure and
squeezing pain and pain evoked by pressure. However, it is
difficult to correctly interpret the origin of these types of
pain. CTS commonly causes neuropathic pain due to
median nerve damage and nociceptive pain due to
inflammatory changes of the carpal tunnel; the NPSI refers
to the ‘‘area of pain’’ rather than the projected innervation
territory of the median nerve, and patients described their
pain in the whole hand, including the wrist. Therefore, we
hypothesize that these types of pain might have, in our
patients, a nociceptive origin. Accordingly, we conjecture
that question 9 of the NPSI (is your pain provoked or
increased by pressure on the painful area?), scored high
probably because patients felt more pain when pressing on
their wrist. The concomitant low scores for brush and cold
allodynia (questions 8 and 10) indirectly support this view.
Admittedly, NPSI findings based on patients’ perception
of pain do not provide reliable evidence on the origin of
pain, whether nociceptive or neuropathic pain. However,
we believe that LAC-induced changes of these NPSI items
support the anti-nociceptive activity of this drug [10].
The anti-nociceptive activity of LAC might result from
different mechanisms. LAC selectively induces the
expression of mGlu2 by enhancing the activity of the
nuclear factor (NF)-jB family of transcription factors.
mGlu2 receptors localized in the spinal cord and other
regions of the nociceptive system negatively regulate
glutamate release [10]. However, other animal studies
showing that the LAC effect on pain is modulated by
nicotinic and muscarinic antagonists indicate that the anti-
nociceptive activity of this drug might be mediated through
the cholinergic pathway [26, 27].
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5 Conclusions
A virtually harmless treatment period (4 months) with
LAC in patients with mild to moderate CTS significantly
improved neurophysiological measures, thus demonstrating
a neuroprotective action. We also found a positive impact
on the patient-oriented measures related to sensory func-
tion and pain. Although, in clinical practice, most clini-
cians are accustomed to think of CTS as a condition that
entails surgery, pharmacological treatments should be
taken into account.
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